Description
Description
This page contains brief details about the drug lenvatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Lenvatinib is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Patients who have had an allergic reaction to lenvatinib or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking this medication, as it can impair wound healing and increase the risk of bleeding.
Lenvatinib was first approved by the United States Food and Drug Administration (FDA) in February 2015 for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Since then, it has received additional approvals for other indications, including the treatment of hepatocellular carcinoma (liver cancer) and renal cell carcinoma (kidney cancer).
Mechanism of Action of Lenvatinib
Lenvatinib blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumor cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.
Uses of Lenvatinib
Lenvatinib is a medication that is used to treat several types of cancer, including thyroid, liver, and kidney cancer. In patients with radioactive iodine-refractory differentiated thyroid cancer, it can be used to slow the progression of the disease and reduce tumor size. It is also approved for the treatment of unresectable hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
Lenvatinib Dosage available
Lenvatinib is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up the second dose.
